(Q27853153)

English

Afatinib versus methotrexate as second-line treatment in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck progressing on or after platinum-based therapy (LUX-Head & Neck 1): an open-label, randomised phase 3 trial

scientific article

In more languages

Statements

scholarly article

1 reference

PubMed publication ID

13 November 2016

Afatinib versus methotrexate as second-line treatment in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck progressing on or after platinum-based therapy (LUX-Head & Neck 1): an open-label, randomised phase 3 trial (English)

1 reference

PubMed publication ID

13 November 2016

phase III clinical trial

0 references

0 references

0 references

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

head and neck squamous cell carcinoma

1 reference

based on heuristic

inferred from title

object named as

Lisa F Licitra

4

0 references

19

object named as

Ezra E W Cohen

0 references

author name string

Jean-Pascal H Machiels

1

0 references

Robert I Haddad

2

0 references

Jérôme Fayette

3

0 references

Makoto Tahara

5

0 references

Jan B Vermorken

6

0 references

Paul M Clement

7

0 references

Thomas Gauler

8

0 references

Didier Cupissol

9

0 references

Juan José Grau

10

0 references

Joël Guigay

11

0 references

Francesco Caponigro

12

0 references

Gilberto de Castro

13

0 references

Luciano de Souza Viana

14

0 references

Ulrich Keilholz

15

0 references

Joseph M Del Campo

16

0 references

Xiuyu Julie Cong

17

0 references

Eva Ehrnrooth

18

0 references

publication date

May 2015

0 references

Lancet Oncology Commission

0 references

16

0 references

5

0 references

583-94

0 references

A retrospective analysis of the outcome of patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck refractory to a platinum-based chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2970124-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Overview of the efficacy of cetuximab in recurrent and/or metastatic squamous cell carcinoma of the head and neck in patients who previously failed platinum-based therapies

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2970124-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Chemotherapy options for patients with metastatic or recurrent squamous cell carcinoma of the head and neck

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2970124-5

7 January 2021

based on heuristic

inferred from DOI database lookup

State-of-the-art and emerging treatment options in the management of head and neck cancer: news from 2013.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2970124-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Open-Label, Uncontrolled, Multicenter Phase II Study to Evaluate the Efficacy and Toxicity of Cetuximab As a Single Agent in Patients With Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck Who Failed to Respond to Platinum-Base

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2970124-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2970124-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Platinum-based chemotherapy plus cetuximab in head and neck cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2970124-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Zalutumumab plus best supportive care versus best supportive care alone in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck after failure of platinum-based chemotherapy: an open-label, randomised phase 3 trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2970124-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase III study of gefitinib compared with intravenous methotrexate for recurrent squamous cell carcinoma of the head and neck [corrected].

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2970124-5

7 January 2021

based on heuristic

inferred from DOI database lookup

The ERBB network: at last, cancer therapy meets systems biology.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2970124-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Signal integration: a framework for understanding the efficacy of therapeutics targeting the human EGFR family

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2970124-5

7 January 2021

based on heuristic

inferred from DOI database lookup

BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2970124-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Target binding properties and cellular activity of afatinib (BIBW 2992), an irreversible ErbB family blocker

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2970124-5

7 January 2021

based on heuristic

inferred from DOI database lookup

A randomized, phase II study of afatinib versus cetuximab in metastatic or recurrent squamous cell carcinoma of the head and neck

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2970124-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Squamous cell carcinoma of the head and neck: EHNS-ESMO-ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2970124-5

7 January 2021

based on heuristic

inferred from DOI database lookup

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2970124-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Correcting for noncompliance and dependent censoring in an AIDS Clinical Trial with inverse probability of censoring weighted (IPCW) log-rank tests.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2970124-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Evidence for a causal association between human papillomavirus and a subset of head and neck cancers

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2970124-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Integrative and comparative genomic analysis of HPV-positive and HPV-negative head and neck squamous cell carcinomas

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2970124-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Comprehensive genomic characterization of head and neck squamous cell carcinomas

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2970124-5

7 January 2021

based on heuristic

inferred from DOI database lookup

P16INK4A as a surrogate biomarker for human papillomavirus-associated oropharyngeal carcinoma: consideration of some aspects

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2970124-5

7 January 2021

based on heuristic

inferred from DOI database lookup

A comprehensive evaluation of human papillomavirus positive status and p16INK4a overexpression as a prognostic biomarker in head and neck squamous cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2970124-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Impact of tumor HPV status on outcome in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck receiving chemotherapy with or without cetuximab: retrospective analysis of the phase III EXTREME trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2970124-5

7 January 2021

based on heuristic

inferred from DOI database lookup

p16 protein expression and human papillomavirus status as prognostic biomarkers of nonoropharyngeal head and neck squamous cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2970124-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Progression-free survival as an end-point in solid tumours--perspectives from clinical trials and clinical practice

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2970124-5

7 January 2021

based on heuristic

inferred from DOI database lookup

To treat or not to treat: balancing therapeutic outcomes, toxicity and quality of life in patients with recurrent and/or metastatic head and neck cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2970124-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Quality of life of patients receiving platinum-based chemotherapy plus cetuximab first line for recurrent and/or metastatic squamous cell carcinoma of the head and neck

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2970124-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Diarrhea associated with afatinib: an oral ErbB family blocker

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2970124-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Dermatologic adverse events associated with afatinib: an oral ErbB family blocker.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2970124-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S1470-2045(15)70124-5

1 reference

Consolidated OpenCitations Corpus – April 2017

OpenCitations bibliographic resource ID

OpenCitations bibliographic resource ID

1 reference

Consolidated OpenCitations Corpus – April 2017

OpenCitations bibliographic resource ID

PubMed publication ID

1 reference

Consolidated OpenCitations Corpus – April 2017

OpenCitations bibliographic resource ID

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q27853153&oldid=1675920198"